Shaoqi Zong1, Hongjia Li2, Qi Shi2, Shanshan Liu2, Wen Li3, Fenggang Hou4. 1. Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai 200071, China. Electronic address: vigilucky@126.com. 2. Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai 200071, China. 3. Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai 200071, China. Electronic address: 13917367207@163.com. 4. Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai 200071, China. Electronic address: fghou555@hotmail.com.
Abstract
BACKGROUND: We sought to comprehensively summarize available evidence for the use of VEGF-C protein to evaluate the clinicopathological and prognostic role of VEGF-C in colorectal cancer. METHODS: Electronic databases from inception to February 2016 were used to search without language restrictions for original articles. A meta-analysis was undertaken to assess the relationship between VEGF-C expression and overall survival (OS) in colorectal cancer. RESULTS: Twenty-seven studies were included in the final meta-analysis. We aggregated 13 trials (n=1.428 patients) that evaluated the correlation between OS and VEGF-C overexpression. Statistics were performed for OS (HR=1.95; 95%CI=1.31-2.92, P=0.007). When the studies were stratified by the pathological variables, including T stage (n=383 patients; OR=1.79; 95%CI=1.14-2.81), lymph node metastasis (n=3212 patients; OR=4.21; 95%CI=3.49-5.08), M stage (n=1106 patients; OR=4.46; 95%CI=2.96-6.70), vascular invasion(n=1471 patients; OR=2.18; 95%CI=1.65-2.88), lymph invasion (n=831 patients; OR=3.95; 95%CI=2.80-5.56), histo-differentiation (n=1695 patients; OR=1.34; 95%CI=1.00-1.79) and Duke's stage(n=778 patients; OR=4.90; 95%CI=3.55-6.75), TNM stage (n=808 patients; OR=1.73; 95%CI=1.18-2.54) provided critical and comprehensive prognostic information. CONCLUSION: Our results demonstrated that VEGF-C overexpression was associated with OS in colorectal cancer.
BACKGROUND: We sought to comprehensively summarize available evidence for the use of VEGF-C protein to evaluate the clinicopathological and prognostic role of VEGF-C in colorectal cancer. METHODS: Electronic databases from inception to February 2016 were used to search without language restrictions for original articles. A meta-analysis was undertaken to assess the relationship between VEGF-C expression and overall survival (OS) in colorectal cancer. RESULTS: Twenty-seven studies were included in the final meta-analysis. We aggregated 13 trials (n=1.428 patients) that evaluated the correlation between OS and VEGF-C overexpression. Statistics were performed for OS (HR=1.95; 95%CI=1.31-2.92, P=0.007). When the studies were stratified by the pathological variables, including T stage (n=383 patients; OR=1.79; 95%CI=1.14-2.81), lymph node metastasis (n=3212 patients; OR=4.21; 95%CI=3.49-5.08), M stage (n=1106 patients; OR=4.46; 95%CI=2.96-6.70), vascular invasion(n=1471 patients; OR=2.18; 95%CI=1.65-2.88), lymph invasion (n=831 patients; OR=3.95; 95%CI=2.80-5.56), histo-differentiation (n=1695 patients; OR=1.34; 95%CI=1.00-1.79) and Duke's stage(n=778 patients; OR=4.90; 95%CI=3.55-6.75), TNM stage (n=808 patients; OR=1.73; 95%CI=1.18-2.54) provided critical and comprehensive prognostic information. CONCLUSION: Our results demonstrated that VEGF-C overexpression was associated with OS in colorectal cancer.
Authors: Alexandra R Harris; Savieay Esparza; Mohammad S Azimi; Robert Cornelison; Francesca N Azar; Danielle C Llaneza; Maura Belanger; Alexander Mathew; Svyatoslav Tkachenko; Matthew J Perez; Claire Buchta Rosean; Raegan R Bostic; R Chase Cornelison; Kinsley M Tate; Shayn M Peirce-Cottler; Cherie Paquette; Anne Mills; Charles N Landen; Jeff Saucerman; Patrick M Dillon; Rebecca R Pompano; Melanie A Rutkowski; Jennifer M Munson Journal: Front Oncol Date: 2022-03-17 Impact factor: 5.738